All Oncology News

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.

Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a clinical trial?

Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.

Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.

Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.

Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.